Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0002089213-25-000003
Filing Date
2025-10-09
Accepted
2025-10-09 18:49:05
Documents
2
Period of Report
2025-10-01

Document Format Files

Seq Description Document Type Size
1 form3-10092025_101001.html 3  
1 form3-10092025_101001.xml 3 11019
2 ex24-10092025_101006.htm EX-24 6794
  Complete submission text file 0002089213-25-000003.txt   19326
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Issuer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O SANGAMO THERAPEUTICS, INC. 501 CANAL BOULEVARD RICHMOND CA 94804
Business Address
Jain Nikunj (Reporting) CIK: 0002089213 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-30171 | Film No.: 251386080